drugset / Trial / NCT00437840

A Study To Investigate The Safety, Tolerability And Blood Levels Of GSK598809

NCT00437840

Phase 1 Completed 12 enrolled GlaxoSmithKline
RandomizedSingle-groupTreatment

Summary

GSK598809 is being developed to facilitate overcoming an addiction to nicotine and to help people stop smoking. This study will investigate if GSK598809 is safe and tolerated in people who smoke and will also look at blood levels of GSK598809 and nicotine.

Timeline

Start
2007-03-20
Primary completion
2007-06-20
Completion
2007-06-20

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK598809 Unknown 10 mg Oral
Subject GSK598809 Unknown 25 mg Oral
Subject GSK598809 Unknown 75 mg Oral

Indications